Abstract
Analysis of 501 melanoma exomes identified RASA2, encoding a RasGAP, as a tumor-suppressor gene mutated in 5% of melanomas. Recurrent loss-of-function mutations in RASA2 were found to increase RAS activation, melanoma cell growth and migration. RASA2 expression was lost in >= 30% of human melanomas and was associated with reduced patient survival. These findings identify RASA2 inactivation as a melanoma driver and highlight the importance of RasGAPs in cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 1408-1410 |
| Number of pages | 3 |
| Journal | Nature Genetics |
| Volume | 47 |
| Issue number | 12 |
| DOIs | |
| State | Published - 1 Dec 2015 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Genetics
Fingerprint
Dive into the research topics of 'Recurrent inactivating RASA2 mutations in melanoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver